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Between 1 October 2016 and 31 August 2017, 51 
Legionnaires’ disease (LD) cases from the United 
Kingdom, Sweden and the Netherlands were identified 
with associated travel to Dubai. Cases did not all stay 
in the same accommodation, indicating that no single 
accommodation could be the source for all these infec-
tions. While local investigations continue into other 
potential sources, clinicians should remain alert to 
the possibility of LD among travellers returning from 
Dubai with respiratory illness.
In December 2016, the European Centre for Disease 
Prevention and Control (ECDC) reported an increase 
in Legionnaires’ disease (LD) cases associated with 
travel to Dubai, United Arab Emirates (UAE) [1] based 
on cases reported to ELDSNet (European Legionnaires’ 
disease surveillance network), an ECDC–operated sur-
veillance system among European Union (EU) coun-
tries, Iceland and Norway [2] for laboratory-confirmed, 
travel-associated LD (TALD) cases who stayed in com-
mercial accommodation site(s) (e.g. hotels) during the 
2–10-day incubation period. As this increase in Dubai-
associated TALD cases continues, we describe cases 
reported with symptom onset between 1 October 2016 
and 31 August 2017 among residents from the United 
Kingdom (UK), Sweden and the Netherlands (the three 
countries that were initially reporting the largest num-
bers of cases). We describe the ongoing situation as at 
18 September 2017 to provide further insight into the 
observed increase and create awareness among phy-
sicians and travellers returning with compatible symp-
toms to consider legionella as a differential diagnosis 
[1].
Case definition
Cases were classified as any person resident in the UK, 
Sweden or the Netherlands with clinical or radiologi-
cal evidence of pneumonia, laboratory confirmation 
of Legionella infection and stay in Dubai during the 
2–10 days before symptom onset. Laboratory confir-
mation included methods fulfilling the EU confirmed 
case definition (culture testing, urine antigen testing 
or serology) or the detection of Legionella spp. by PCR 
[3]. All patients meeting the case definition with symp-
tom onset between 1 October 2016 and 31 August 2017, 
were described by age, sex, tobacco smoking status, 
presence of underlying medical conditions, laboratory 
confirmation method and where available, sequence-
based typing.
Surveillance
The LD surveillance systems in our countries have been 
described elsewhere [4-7]. In brief, LD must be notified 
by medical practitioners to public health authorities, 
who interview the patient or close family members 
to identify potential legionella exposures during the 
incubation period, including any travel away from the 
patient’s main residence (national and/or foreign 
travel).
Description of cases
There were 51 laboratory-confirmed LD cases associ-
ated with travel to Dubai with symptom onset between 
1 October 2016 and 31 August 2017. Of these, 36 
were reported from the UK, eight from Sweden and 
seven from the Netherlands. Over two thirds of cases 
were men (36/51). The median age for all cases was 
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66 years (interquartile range (IQR): 57.5−72.0; range: 
36−84 years). For cases with available information, 
23/43 were smokers or ex-smokers and 18/44 had at 
least one long-term underlying medical condition. Just 
over a quarter of cases with hospitalisation informa-
tion (10/36), required critical care admission. Figure 
1 shows the distribution of cases by symptom onset 
date, and indicates cases concentrated in October 
2016, with continuing elevated numbers in November, 
early December 2016, February and April 2017.
The most frequently used diagnostic method was uri-
nary antigen testing (45/51 cases) with PCR methods 
used in 17/51 cases and culture in 7/51 cases; 14 cases 
were diagnosed using more than one type of labora-
tory test. Most cases were speciated as Legionella 
pneumophila (50/51), while the remaining case was 
Legionella spp. unknown. Serogroup was known for 
16 cases: 13 were serogroup 1, two serogroup 13 and 
one serogroup 2–14. Full sequence-based typing (ST) 
was available for nine cases (6 cases ST616, 3 cases 
ST1327) and three cases had partial ST profiles.
The median number of days within the incubation 
period that cases spent in Dubai was six (IQR: 4−8, 
range 2–9 days). Eleven cases spent the whole incuba-
tion period in Dubai. Four cases also travelled to other 
emirates within UAE; six had foreign travel to four dif-
ferent countries in addition to UAE, during the incuba-
tion period.
In relation to potential aerosol exposures in Dubai, 44 
of 48 cases with available information had used show-
ers, while 29 of 45 recalled exposures to fountains and 
water features. Use of swimming pools (12/40) and spa 
pools (5/39) was less frequent among cases. Other 
activities for cases included boat trips (7 cases), foun-
tain shows and visits to the gold souk (3 cases each).
The 51 cases were associated with 45 individual accom-
modation sites. Most (43/51) cases stayed in commer-
cial accommodation: 27/43 in single accommodation 
(sites where there were no other associated cases in 
the previous two years), 15/43 in cluster accommoda-
tion (sites where there were two or more associated 
cases in a two-year period) and 1/43 in a commercial 
accommodation with limited information (preventing 
the identification of associated cases in the previ-
ous two years); seven stayed in private accommoda-
tion and for one case the accommodation type was 
unknown. Significantly, in addition to the seven pri-
vate accommodation sites, there were 27 different 
commercial accommodation sites not previously asso-
ciated with LD cases (i.e. not part of clusters them-
selves). Three of the 51 cases were associated with a 
foreign-travel related cluster in other countries. The 
cases for whom sequence-based typing was available 
were all linked to different accommodations sites. The 
average case numbers recorded for each month by 
onset date between October and August for 2013−14, 
2014−15, 2015−16 and - separately for October 2016 to 
August 2017 for our three countries, are summarised 
in the Table, which shows that during the investigation 
period, the number of Dubai-associated TALD cases 
was higher than the rounded average case numbers of 
3−12 cases for the equivalent 11-month period for each 
of our countries between 2013 and 2016.
Figure 2 shows that cumulative case numbers for 
all three countries were particularly elevated from 
September 2016 onwards, compared with average 
monthly cumulative case numbers reported for 2013–
15. This was sustained for all three countries through 
to August 2017.
Discussion
Here we report an increase in Dubai-associated TALD 
cases, above the historical averages for each of our 
Figure 1
Cases of Legionnaires’ disease associated with travel to Dubai in residents of the United Kingdom, Sweden and the 
Netherlands, 1 October 2016−31 August 2017 (n=51)
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three countries. As our countries’ travellers accounted 
for the majority of the increase when first observed by 
ECDC [1], they provide an important insight into this 
situation.
The hypothesis of increased LD risk related to travel to 
Dubai rather than increased risk in the countries of res-
idence is supported by the simultaneous peak in cases 
occurring from September 2016 onwards for all three 
countries (Table). Additionally, there were no changes 
in LD surveillance and no community outbreaks in our 
countries that provide an alternative explanation. Six 
cases were typed as ST616, a strain observed in our 
surveillance only in cases associated with travel to 
Dubai. In addition, ST1327 has been associated with 
travel to Dubai for all but one case in our surveillance 
(data not shown). Furthermore, 11 cases spent their 
entire incubation period in Dubai. These findings sup-
port the assertion that these infections occurred within 
Dubai.
There are several potential explanations for the 
observed increase in cases associated with travel to 
Dubai; one could be changes in patient-level risk fac-
tors for infection. However, this is unlikely to explain 
the increase as patient-level risk factors such as under-
lying medical conditions, current or previous smoking 
status were reported for 36 cases, which is consistent 
with almost three quarters among LD cases, previously 
reported in England and Wales in 2015 [7].
Another potential explanation is an increase in travel-
lers, although overall changes in traveller numbers do 
not solely explain the scale of the observed increase. 
UK traveller numbers to Dubai increased by 5% for the 
calendar year from 2015 to 2016 [8] while travellers to 
UAE from the Netherlands increased by 9% between 
November 2016 and April 2017 compared with the 
same time period one year earlier (data not shown); 
however, the proportion of the latter dataset related to 
Dubai specifically is unknown. Due to the incomplete 
availability of Dubai-specific travel data for all three 
countries as well as the limited comparability of these 
available data sources, we have not specifically esti-
mated an incidence rate for LD cases associated with 
travel to Dubai.
Another explanation is one or more new legionella 
source(s) in Dubai, although there is limited informa-
tion available from local investigations. TALD investi-
gations generally focus on accommodation sites [2]. 
However, these accommodation sites seem an unlikely 
explanation as only 15 cases were associated with clus-
ter sites. Therefore, wider environmental investigations 
in addition to commercial accommodation sites are 
required to identify and control the source of infection.
ECDC reported that there has been no increase in pneu-
monia notifications locally in Dubai between October 
and December 2016 [9]. This could be explained by an 
environmental source where foreign travellers are more 
frequently exposed than local residents. Alternatively, 
the local Dubai population is predominantly young, 
with only 8.7% in the ≥50 age group in 2016, and there-
fore is potentially at lower LD risk [10].
Several public health actions have been undertaken. 
To support local investigations, anonymised epidemio-
logical information collected by the public health agen-
cies in the EU countries has been shared with public 
health authorities in Dubai by ECDC and the World 
Health Organization (WHO). This supplements our rou-
tine international TALD case reporting via ELDSNet. 
Similar information sharing for 17 TALD cases from dif-
ferent countries was successful in controlling an out-
break in Lazise, Italy, in 2011 [11].
Although the absolute numbers of Dubai-related TALD 
cases are low in comparison to annual visitor numbers, 
information for travellers about LD symptoms to be 
aware of has been published on websites of national 
public health institutes and on websites for travel 
health [12-14].
This investigation highlights the benefits of interna-
tional TALD surveillance (such as ELDSNet) in facilitat-
ing identification and alerting of increases in cases 
related to specific destinations; in addition, ascertain-
ment of cases linked to private accommodation, as well 
as commercial accommodation, through such surveil-
lance, would be important to determine the full scale 
of TALD in this particular situation. It should be noted 
that there would be an inherent delay in reporting to 
ECDC due to the time taken for diagnosis and collation 
of relevant epidemiological data.
Figure 2
Cumulative number of Legionnaires’ disease cases 
associated with travel to Dubai in residents of the United 
Kingdom, Sweden and the Netherlands, January 2016−
August 2017 compared to the average for 2013−15
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United Kingdom, Sweden and the Netherlands, combined.
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Seasonal trends in travel to Dubai highlight the poten-
tial for further cases occurring in the coming months; 
for instance travel from the UK is particularly high dur-
ing the winter and spring seasons [8]. Thus further 
environmental investigations remain important. While 
local public health authorities in Dubai conduct pub-
lic health investigations and implement controls, clini-
cians should remain vigilant for LD symptoms among 
returning travellers, to aid prompt diagnosis and 
treatment.
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Table
Average numbers of Legionnaires’ disease cases associated with travel to Dubai between 1 October and 31 August for 
2013−14, 2014−15 and 2015−16 compared with case numbers for 2016−17
Country of residence
Number of LD cases associated with travel to 
Dubai 
(1 Oct 2016−31 Aug 17)
Rounded average number of LD cases associated with 
travel to Dubai 
(1 Oct 2013−15 to 31 Aug 2014−16)
United Kingdom 36 12
Sweden 8 3
The Netherlands 7 4
LD: Legionnaires’ disease.
